-
-
-
-
-
-
-
Syndax Pharmaceuticals (SNDX) PT Raised to $56 at BTIG
-
-
-
-
-
-
-
Syndax Pharmaceuticals (SNDX) PT Lowered to $31 at Goldman Sachs
-
-
-
-
-
-
-
Syndax Pharmaceuticals (SNDX) PT Raised to $45 at H.C. Wainwright
-
-
-
-
-
-
-
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
-
-
-
-
-
-
-
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
-
-
-
-
-
-
-
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
-
-
-
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

